ENA Respiratory announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled “Novel molecules” (US 18/112091), which covers the company’s INNA-051 intranasal TLR2/6 agonist. According to ENA, INNA-051 is now covered by 30 patents in the US, Europe, and other markets.
The FDA recently cleared the company’s IND for a Phase 1b study of a dry powder formulation of INNA-051. In 2022, the COPD Foundation partnered with ENA Respiratory on development of INNA-051 as a pan-antiviral nasal spray, and the dry powder formulation project has been funded in part by the US Department of Defense Chemical and Biological Defense Program.
ENA Respiratory CEO Christophe Demaison commented, “Our IP portfolio provides robust and long-lasting protection with potential exclusivity for INNA-051 out to at least 2042 and likely for 5 years post that date. This gives us great confidence in the future global commercial value of our innate immune modulators as we continue to drive forwards in clinical development.”
Read the ENA Respiratory press release.
